RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
+17.86%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$345M
AUM Growth
+$345M
(+5.6%)
Cap. Flow
-$46M
Cap. Flow
% of AUM
-13.33%
Top 10 Holdings %
Top 10 Hldgs %
30.53%
Holding
110
New
11
Increased
34
Reduced
37
Closed
25
Top Buys
| 1 |
Gilead Sciences
GILD
|
$12.6M |
| 2 |
CELG
Celgene Corp
CELG
|
$11.4M |
| 3 |
Universal Technical Institute
UTI
|
$6.79M |
| 4 |
RCPT
RECEPTOS INC COM STK (DE)
RCPT
|
$6.44M |
| 5 |
Regeneron Pharmaceuticals
REGN
|
$3.9M |
Top Sells
| 1 |
Dynavax Technologies
DVAX
|
$18.6M |
| 2 |
Universal Health Services
UHS
|
$10.3M |
| 3 |
Alkermes
ALKS
|
$7.2M |
| 4 |
Medtronic
MDT
|
$7.13M |
| 5 |
NPSP
NPS PHARMACEUTICALS INC
NPSP
|
$4.83M |
Sector Composition
| 1 | Healthcare | 80.57% |
| 2 | Consumer Staples | 1.97% |
| 3 | Financials | 1.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
CELG
1
DELISTED
Celgene Corp
CELG
| $20.4M | 5.9% | 182,000 +102,000 | +128% | +$11.4M |
|
|
2
Gilead Sciences
GILD
$140B
| $19.4M | 5.63% | 206,138 +134,138 | +186% | +$12.6M |
|
3
CVS Health
CVS
$92.8B
| $9.34M | 2.71% | 97,000 +25,000 | +35% | +$2.41M |
|
|
4
Regeneron Pharmaceuticals
REGN
$61.5B
| $9.23M | 2.68% | 22,500 +9,500 | +73% | +$3.9M |
|
5
AbbVie
ABBV
$372B
| $9.16M | 2.66% | 140,000 +29,000 | +26% | +$1.9M |
|
|
6
Alkermes
ALKS
$4.78B
| $8.37M | 2.43% | 143,000 -123,000 | -46% | -$7.2M |
|
|
ALXN
7
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $8.14M | 2.36% | 44,000 -14,000 | -24% | -$2.59M |
|
8
Biogen
BIIB
$19.4B
| $7.3M | 2.12% | 21,500 -7,500 | -26% | -$2.55M |
|
|
MDVN
9
DELISTED
MEDIVATION, INC.
MDVN
| $7.04M | 2.04% | 70,700 +32,700 | +86% | +$3.26M |
|
|
AGN
10
DELISTED
Allergan plc
AGN
| $6.95M | 2.01% | 27,000 +7,000 | +35% | +$1.8M |
|
11
Bristol-Myers Squibb
BMY
$96B
| $6.79M | 1.97% | 115,000 +16,000 | +16% | +$944K |
|
|
12
Universal Technical Institute
UTI
$1.45B
| $6.79M | 1.97% | +61,000 | New | +$6.79M |
|
13
UnitedHealth
UNH
$281B
| $6.77M | 1.96% | 67,000 +32,000 | +91% | +$3.23M |
|
|
RCPT
14
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
| $6.44M | 1.87% | +52,526 | New | +$6.44M |
|
15
Amgen
AMGN
$155B
| $6.24M | 1.81% | 39,168 +16,168 | +70% | +$2.58M |
|
16
Esperion Therapeutics
ESPR
$448M
| $6.07M | 1.76% | 150,000 +67,079 | +81% | +$2.71M |
|
|
RAD
17
DELISTED
Rite Aid Corporation
RAD
| $5.9M | 1.71% | 785,000 -333,000 | -30% | -$2.5M |
|
|
COV
18
DELISTED
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
| $5.83M | 1.69% | 57,000 -19,000 | -25% | -$1.94M |
|
19
Cardinal Health
CAH
$35.5B
| $5.65M | 1.64% | 70,000 +11,000 | +19% | +$888K |
|
20
BioMarin Pharmaceuticals
BMRN
$11.2B
| $5.51M | 1.6% | 61,000 -31,000 | -34% | -$2.8M |
|
21
Acadia Pharmaceuticals
ACAD
$4.38B
| $5.24M | 1.52% | 165,000 -54,000 | -25% | -$1.71M |
|
22
Elevance Health
ELV
$71.8B
| $5.15M | 1.49% | 41,000 +6,000 | +17% | +$754K |
|
|
CLVS
23
DELISTED
Clovis Oncology, Inc.
CLVS
| $4.78M | 1.39% | 85,398 +28,398 | +50% | +$1.59M |
|
24
Eli Lilly
LLY
$657B
| $4.55M | 1.32% | 66,000 +36,000 | +120% | +$2.48M |
|
25
Merck
MRK
$210B
| $4.54M | 1.32% | 80,000 +15,000 | +23% | +$852K |
|